JP2023514347A5 - - Google Patents
Info
- Publication number
- JP2023514347A5 JP2023514347A5 JP2022549518A JP2022549518A JP2023514347A5 JP 2023514347 A5 JP2023514347 A5 JP 2023514347A5 JP 2022549518 A JP2022549518 A JP 2022549518A JP 2022549518 A JP2022549518 A JP 2022549518A JP 2023514347 A5 JP2023514347 A5 JP 2023514347A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- here
- transplant
- approximately
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978141P | 2020-02-18 | 2020-02-18 | |
| US62/978,141 | 2020-02-18 | ||
| US202063062845P | 2020-08-07 | 2020-08-07 | |
| US63/062,845 | 2020-08-07 | ||
| PCT/US2021/018599 WO2021168128A1 (en) | 2020-02-18 | 2021-02-18 | Compositions and methods for allogeneic transplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514347A JP2023514347A (ja) | 2023-04-05 |
| JP2023514347A5 true JP2023514347A5 (enExample) | 2024-02-26 |
Family
ID=77391794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549518A Pending JP2023514347A (ja) | 2020-02-18 | 2021-02-18 | 同種移植のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390412A1 (enExample) |
| EP (1) | EP4107188A4 (enExample) |
| JP (1) | JP2023514347A (enExample) |
| KR (1) | KR20220154676A (enExample) |
| CN (1) | CN115397444A (enExample) |
| AU (1) | AU2021224663A1 (enExample) |
| CA (1) | CA3168039A1 (enExample) |
| IL (1) | IL295653A (enExample) |
| MX (1) | MX2022009885A (enExample) |
| WO (1) | WO2021168128A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292628A (en) | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
| US12496303B2 (en) * | 2020-10-19 | 2025-12-16 | Washington University | Conditioning agents for use in allogeneic hematopoietic stem cell transplantation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170226209A1 (en) * | 2014-08-01 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| EP4417210A1 (en) * | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
-
2021
- 2021-02-18 WO PCT/US2021/018599 patent/WO2021168128A1/en not_active Ceased
- 2021-02-18 KR KR1020227028992A patent/KR20220154676A/ko active Pending
- 2021-02-18 MX MX2022009885A patent/MX2022009885A/es unknown
- 2021-02-18 AU AU2021224663A patent/AU2021224663A1/en active Pending
- 2021-02-18 IL IL295653A patent/IL295653A/en unknown
- 2021-02-18 CA CA3168039A patent/CA3168039A1/en active Pending
- 2021-02-18 CN CN202180027333.1A patent/CN115397444A/zh active Pending
- 2021-02-18 JP JP2022549518A patent/JP2023514347A/ja active Pending
- 2021-02-18 EP EP21756915.1A patent/EP4107188A4/en active Pending
-
2022
- 2022-08-17 US US17/820,540 patent/US20230390412A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6748221B2 (ja) | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 | |
| JP6018622B2 (ja) | Ｃｄ３７結合性分子及びその免疫複合体 | |
| Sullivan-Chang et al. | Targeting CD22 in B-cell malignancies: current status and clinical outlook | |
| JP2022512781A5 (enExample) | ||
| JP2022163075A (ja) | 細胞の枯渇のための組成物および方法 | |
| ES2882360T3 (es) | Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| US20210379195A1 (en) | Methods for allogeneic hematopoietic stem cell transplantation | |
| JP2018522833A (ja) | キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療 | |
| Persaud et al. | Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation | |
| HUE031533T2 (hu) | CD19-kötõszerek valamint alkalmazásuk | |
| Cipkar et al. | Antibodies and bispecifics for multiple myeloma: effective effector therapy | |
| CN116940386A (zh) | 吡咯并苯并二氮杂䓬-抗体缀合物以及其用途 | |
| CN102271711B (zh) | 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂 | |
| CN118356508A (zh) | 使用抗体-药物缀合物调节免疫应答 | |
| JP2023514347A5 (enExample) | ||
| US20240245753A1 (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| CA3114922A1 (en) | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy | |
| CA3183602A1 (en) | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates | |
| US20220273811A1 (en) | Methods and compositions for treating autoimmune diseases | |
| US20240148890A1 (en) | Anti-folate receptor conjugate therapy for cancer treatment | |
| US20220347313A1 (en) | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | |
| ES2213355T3 (es) | Cocteles de inmunotoxinas para el tratamiento de enfermedades de origen inmunologico. | |
| EP4054647A1 (en) | Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection | |
| Routledge | Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma |